9,010 results
ref. DADAX0367567377New unknown
ref. DADAX036733660XNew unknown
ref. DADAX041554002XNew unknown
ref. DADAX0367173751New unknown
ref. DADAX0367178826New unknown
ref. DADAX0415509033New unknown
ref. DADAX0367319306New unknown
ref. DADAX0415814448New unknown
ref. DADAX0367221926New unknown
ref. DADAX0415629160New unknown
ref. DADAX0419258000New unknown
ref. DADAX0415356768New unknown
ref. DADAX0415527120New unknown
ref. DADAX0415857392New unknown
ref. DADAX0865714479New unknown
ref. DADAX0081014473New unknown
ref. DADAX0792353013New unknown
1978ref. 62778Washington DC: U.S. Government Printing Office 1978. Presumed first edition/first printing. Wraps. Good. No dust jacket as issued. Part I ONLY. 24 cm. xi 1402 pages. Serial No. 95-169. H.R. 11611 was sponsord by seven members of the subcommittee and was seen as having the potential of bringing the benefits of promising new drug therapies to the marketplace more rapidly without compromising safety or effectiveness and possibly reducing the costs of drugs. This contains an imnmense amount of information. U.S. Government Printing Office paperback
ref. SONG1563381818Used: Good unknown
ref. DADAX0471762725New unknown
ref. DADAX8120304993New unknown
ref. DADAX3642069002New unknown
ref. DADAX148222738XNew unknown
ref. DADAX0415713234New unknown
ref. DADAX0415510007New unknown